Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

Cancer Immunology Research

Volumn 3, Issue 2, 2015, Pages 136-148

  Shen, Li ^a   Sundstedt, Anette ^b   Ciesielski, Michael ^c   Miles, Kiersten Marie ^a   Celander, Mona ^b   Adelaiye, Remi ^a   Orillion, Ashley ^a   Ciamporcero, Eric ^a   Ramakrishnan, Swathi ^a   Ellis, Leigh ^a   Fenstermaker, Robert ^c   Abrams, Scott I ^c   Eriksson, Helena ^b   Leanderson, Tomas ^b,d   Olsson, Anders ^b   Pili, Roberto ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Active Biotech Research AB   (Sweden)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; NITRIC OXIDE SYNTHASE; PEPTIDE VACCINE; SURVIVIN; TASQUINIMOD; ANTINEOPLASTIC AGENT; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CELL POPULATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; MALE; MELANOMA B16; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CASTRATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSTATIC NEOPLASMS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CASTRATION; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; IMMUNE TOLERANCE; IMMUNOTHERAPY; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; QUINOLINES; T-LYMPHOCYTE SUBSETS;

EID: 84962290319     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0036     Document Type: Article

References (53)

1. Small EJ, Schellhammer PF, Higano C.S., Redfern CH, Nemunaitis JJ, Valone FH, et al Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
2. Smith JL J.r., Stehlin JS Jr. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 1965;18:1399-415.
3. Culver ME, Gatesman ML, Mancl E.E., Lowe DK. Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 2011;45:510-9.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
5. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005;207:147-55.
6. Pan PY, Wang GX, Yin B, Ozao J., Ku T, Divino CM, Chen SH Reversion of immune tolerance in advanced malignancy: modulation of myeloidderived suppressor cell development by blockade of stem-cell factor function. Blood 2008;111:219-28.
7. Sinha P, Clements VK, Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-13.
8. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005;175: 8200-8.
9. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011;90:31-6.
10. + immature myeloid suppressor cells mediate the development of tumor induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-31.
11. Serafini P, Mgebroff S, Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439-49.
12. Yang Z, Zhang B, Li D., Lv M, Huang C, Shen G.X., Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor micro-environment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE 2010;5:e8922.
13. Mills CD, Kincaid K, Alt J.M., Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166-73.
14. Pili R, Haggman M, Stadler W.M., Gingrich JR, Assikis VJ, Bjork A, et al Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022-8.
15. Armstrong AJ, Haggman M, Stadler W.M., Gingrich JR, Assikis V, Polikoff J, et al Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res 2013;19: 6891-901.
16. Dalrymple SL, Becker RE, Isaacs JT The quinoline-3-carboxamide antiangiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007;67:790-7.
17. Dalrymple SL, Becker RE, Zhou H, DeWeese T.L., Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 2012;72:638-48.
18. Jennbacken K, Welen K, Olsson A., Axelsson B, Torngren M, Damber J.E., et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 2012;72:913-24.
19. Isaacs JT, Pili R, Qian D.Z., Dalrymple SL, Garrison JB, Kyprianou N, et al Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006;66:1768-78.
20. Olsson A, Bjork A, Vallon-Christersson J, Isaacs J.T., Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010;9:107.
21. Isaacs JT, Antony L, Dalrymple S.L., Brennen WN, Gerber S, Hammers H, et al Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer micro environment. Cancer Res 2013;73: 1386-99.
22. Bjork P, Bjork A, Vogl T., Stenstrom M, Liberg D, Olsson A., et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97.
23. Kallberg E, Vogl T, Liberg D., Olsson A, Bjork P, Wikstrom P., et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS ONE 2012;7:e34207.
24. Cheng P, Corzo CA, Luetteke N, Yu B., Nagaraj S, Bui MM, et al Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49.
25. Sinha P, Okoro C, Foell D., Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid derived suppressor cells. J Immunol 2008;181:4666-75.
26. Ellis L, Lehet K, Ramakrishnan S., Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. Prostate 2011;72:587-91.
27. Mulryan K, Ryan MG, Myers K.A., Shaw D., Wang W, Kingsman SM, et al Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol CancerTher 2002;1:1129-37.
28. Attia MA, Weiss DW Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 1966;26: 1787-800.
29. Kishi H, Igawa M, Kikuno N., Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004;171: 1855-60.
30. Ciesielski MJ, Ahluwalia MS, Munich S.A., Orton M., Barone T, Chanan-Khan A, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 2010;59:1211-21.
31. Shen L, Ciesielski M, Ramakrishnan S., Miles KM, Ellis L, Sotomayor P, et al Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 2012;7:e30815.
32. Dohlsten M, Abrahmsen L, Bjork P., Lando PA, Hedlund G, Forsberg G, et al Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 1994;91:8945-9.
33. Kappler J, Kotzin B, Herron L., Gelfand EW, Bigler RD, Boylston A, et al V beta-specific stimulation ofhumanTcells by staphylococcal toxins. Science 1989;244:811-3.
34. Raymond E, Dalgleish A, Damber J.E., Smith M., Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 2014;73:1-8.
35. De Palma M., Venneri MA, Galli R, SergiSergi L., Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
36. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66.
37. Peranzoni E, Zilio S, Marigo I., Dolcetti L, Zanovello P, Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010;22:238-44.
38. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-44.
39. El Kasmi K.C., Qualls JE, Pesce J.T., Smith AM, Thompson RW, Henao Tamayo M, et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008;9:1399-406.
40. Sundstedt A, Celander M, Eriksson H., Törngren M, Hedlund G. Mono therapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. J Immunother 2012;35:344-53.
41. Rigamonti N, Capuano G, Ricupito A., Jachetti E, Grioni M, Generoso L., et al. Modulators of arginine metabolism do not impact on peripheral Tcell tolerance and disease progression in a model of spontaneous prostate cancer. Clin Cancer Res 2011;17:1012-23.
42. Chen X, Eksioglu EA, Zhou J, Zhang L., Djeu J, Fortenbery N, et al Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 2013;123:4595-611.
43. Ichikawa M, Williams R, Wang L., Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011;9:133-48.
44. Ostrand-Rosenberg S., Sinha P, Beury D.W., Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012;22:275-81.
45. De Palma M., Lewis CE Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
46. Murdoch C, Muthana M, Coffelt S.B., Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
47. Li B, Vincent A, Cates J., Brantley-Sieders DM, Polk DB, Young PP Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 2009;69:338-48.
48. Toh B, Wang X, Keeble J., Sim WJ, Khoo K, Wong WC, et al Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011;9: e1001162.
49. Cui TX, Kryczek I, Zhao L., Zhao E, Kuick R, Roh M.H., et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013;39: 611-21.
50. Hiratsuka S, Watanabe A, Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75.
51. Sawant A, Deshane J, Jules J., Lee CM, Harris BA, Feng X, et al Myeloid derived suppressor cells functionas novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 2013;73:672-82.
52. Kaplan RN, Riba RD, Zacharoulis S, Bramley A.H., Vincent L., Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
53. Acharyya S, Oskarsson T, Vanharanta S., Malladi S, Kim J, Morris P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012;150:165-78.